Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04015375 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Torrent Pharmaceuticals Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
NCT04015375: Completed Phase 3 study, sponsored by Torrent Pharmaceuticals Limited.
NCT04015375 is a Phase 3 study that has completed, run by Torrent Pharmaceuticals Limited. The registered enrollment target is 1,150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04015375, a Phase 3 study, has completed, sponsored by Torrent Pharmaceuticals Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
Study Summary
To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.
Interventions
- DRUG Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
- DRUG ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)
- OTHER Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2020-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04015375
The ClinicalTrials.gov registry entry for NCT04015375 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Torrent Pharmaceuticals Limited, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) is the first listed.
NCT04015375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04015375 about?
NCT04015375 is a clinical study titled "Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris". To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.
What is the current status of trial NCT04015375?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2019-07-11. Estimated completion is 2020-02-22.
What interventions are being tested in trial NCT04015375?
The interventions under investigation include: Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) (DRUG), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.) (DRUG), Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) (OTHER).
Who is sponsoring clinical trial NCT04015375?
This trial is sponsored by Torrent Pharmaceuticals Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.